Other languages Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
7.07 ^USD	+16.86%		+30.93%	+112.95%

Mar. 27	Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	MT
Mar. 25	HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)	Feb. 05
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope	Dec. 14
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 01
Sector Update: Health Care	Dec. 01
Rani Therapeutics Stock Climbs After Share Purchase by CEO	Dec. 01
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform	Nov. 01
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration	23-10-25
Rani Therapeutics Reports 'Successful' Oral Delivery of Humira in High-Capacity Pill in Preclinical Study	23-10-19
Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study	23-10-19
Sector Update: Health Care Stocks Mixed Premarket Monday	23-09-18
Rani Therapeutics Starts Early Stage Trial of Autoimmune Disease Treatment Candidate	23-09-18
Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)	23-09-18
Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies	23-09-07
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Rani Therapeutics Holdings, Inc. Appoints Kate Mckinley as Chief Business Officer	23-05-24
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Lyn Baranowski, A Member of the Board of Directors of Rani Therapeutics Holdings, Inc. and the Compensation Committee and the Nominating and Corporate Governance Committee, Will Not Stand for Re-Election	23-04-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Other languages

Filters